Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 3
2017 3
2020 4
2021 1
2022 2
2023 3
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Antimicrobial stewardship programs in seven Latin American countries: facing the challenges.
Pallares CJ, Porras J, De La Cadena E, García-Betancur JC, Restrepo-Arbeláez N, Viveros SMC, Cornistein W, Castañeda-Méndez P, Cuellar L, Boldim-Ferreira D, Chaverri-Murillo J, Labarca JA, Villegas MV. Pallares CJ, et al. BMC Infect Dis. 2023 Jul 11;23(1):463. doi: 10.1186/s12879-023-08398-3. BMC Infect Dis. 2023. PMID: 37434158 Free PMC article.
Can risk factors and risk scores help predict colonization and infection in multidrug-resistant gram-negative bacteria?
Restrepo-Arbeláez N, García-Betancur JC, Pallares CJ, El Ayoubi LW, Kiratisin P, Kanj SS, Villegas MV. Restrepo-Arbeláez N, et al. Among authors: pallares cj. Antimicrob Steward Healthc Epidemiol. 2024 Nov 11;4(1):e196. doi: 10.1017/ash.2024.455. eCollection 2024. Antimicrob Steward Healthc Epidemiol. 2024. PMID: 39563931 Free PMC article. Review.
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Hardt K, Vandebosch A, Sadoff J, Le Gars M, Truyers C, Lowson D, Van Dromme I, Vingerhoets J, Kamphuis T, Scheper G, Ruiz-Guiñazú J, Faust SN, Spinner CD, Schuitemaker H, Van Hoof J, Douoguih M, Struyf F; ENSEMBLE2 study group. Hardt K, et al. Lancet Infect Dis. 2022 Dec;22(12):1703-1715. doi: 10.1016/S1473-3099(22)00506-0. Epub 2022 Sep 13. Lancet Infect Dis. 2022. PMID: 36113538 Free PMC article. Clinical Trial.
Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries.
Mojica MF, De La Cadena E, Ríos R, García-Betancur JC, Díaz L, Reyes J, Hernández-Gómez C, Radice M, Gales AC, Castañeda Méndez P, Munita JM, Pallares CJ, Martínez JRW, Villegas MV. Mojica MF, et al. Among authors: pallares cj. Front Microbiol. 2022 Oct 24;13:1035609. doi: 10.3389/fmicb.2022.1035609. eCollection 2022. Front Microbiol. 2022. PMID: 36353456 Free PMC article.
In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries.
Appel TM, Mojica MF, De La Cadena E, Pallares CJ, Radice MA, Castañeda-Méndez P, Jaime-Villalón DA, Gales AC, Munita JM, Villegas MV. Appel TM, et al. Among authors: pallares cj. Antibiotics (Basel). 2020 Feb 5;9(2):62. doi: 10.3390/antibiotics9020062. Antibiotics (Basel). 2020. PMID: 32033394 Free PMC article.
Performance of disk diffusion and broth microdilution for fosfomycin susceptibility testing of multidrug-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa.
Mojica MF, De La Cadena E, Hernández-Gómez C, Correa A, Appel TM, Pallares CJ, Villegas MV. Mojica MF, et al. Among authors: pallares cj. J Glob Antimicrob Resist. 2020 Jun;21:391-395. doi: 10.1016/j.jgar.2020.01.003. Epub 2020 Jan 28. J Glob Antimicrob Resist. 2020. PMID: 32004722 Free article.
18 results